Clinical Trial: Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19

U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07861542) titled 'Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19' on Sept. 30.

Brief Summary: The purpose of this study is to evaluate the safety and immunogenicity of a single dose of Sanofi's Omicron subvariant-based Nuvaxovid in participants >= 65 years of age and participants 12 through 64 years of age who have at least one underlying condition that puts them at increased risk for severe outcomes of COVID-19 and who have been previously vaccinated with a COVID-19 vaccine >= 90 days prior to study vaccination.

Study details include:

* The study duration will be approxima...